secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K/A
Filed at:   2022-06-14T23:59:59+00:00
Accession:  0001628280-22-017114
Event type: other_material
Sentiment:  negative
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology shareholders reject advisory vote on executive compensation at 2022 annual meeting
--------------------------------------------------------------------------------

- Corrected voting results show say-on-pay failed: 7.93M For, 7.36M Against, 2.02M Abstain, 12.06M broker non-vote.
- All seven director nominees elected; BDO USA ratified as auditor; amendment to 2021 Omnibus Equity Plan approved.
- Amendment filed to correct original 8-K error in Proposal 4 (advisory vote on executive compensation) results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000162828022017114/0001628280-22-017114-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000162828022017114/crdf-20220609.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-017114

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer